Gemini Therapeutics appoints Jason Meyenburg as CEO

US precision medicine company Gemini Therapeutics, which is focused on developing treatments for age-related macular degeneration (AMD) and linked ocular disorders, has appointed Jason Meyenburg as its Chief Executive Officer (CEO).

Jason Meyenburg will also join the Board of Directors of Gemini Therapeutics.

Stephen Squinto – Gemini Therapeutics Board Director said: “We are thrilled to have Jason assume the helm of Gemini. His leadership experience, industry expertise and passion for driving much-needed therapeutic innovation will help Gemini to maximize the broad opportunities presented by our innovative precision therapeutics pipeline.

“On behalf of the entire company, I want to welcome Jason. I look forward to collaborating with him, the management team and the board as we work together to redefine treatment of AMD through genetics.”

According to Gemini Therapeutics, its therapeutic candidates are matched to molecular abnormalities found in patients having high-risk genetic profiles. The company’s pipeline is said to have monoclonal antibodies, AAV-mediated gene therapies, and recombinant proteins.

Jason Meyenburg – Gemini Therapeutics CEO said: “I am excited to be joining Gemini’s experienced leadership team at a pivotal point in the company’s journey. As we prepare to submit our first IND, advancing therapeutic options for high-risk genetic patient populations of AMD remains our steadfast goal at Gemini. Building out our leadership team is a key component of that progress.”

Jason Meyenburg appointed as Gemini Therapeutics CEO. Photo courtesy of Stuart Miles/Freedigitalphotos.net.

The new Gemini Therapeutics CEO comes from Orchard Therapeutics, where he had been the Chief Commercial Officer. During his stint at Orchard Therapeutics, the company acquired and integrated a gene therapy portfolio from pharma major GlaxoSmithKline and launched an IPO this year.

Before working at Orchard Therapeutics, Jason Meyenburg was Chief Commercial Officer of Vtesse Pharmaceuticals, which is engaged in developing a therapy for the rare disease Niemann-Pick C in partnership with the NIH, and of Sucampo Pharmaceuticals through the acquisition of the company.

Before Vtesse Pharmaceuticals and Sucampo Pharmaceuticals, Jason Meyenburg spent 13 years at Alexion Pharmaceuticals in various roles like Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas.

Related posts

• Genentech bags Rozlytrek FDA approval for two rare types of cancer (0)
• GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group (0)
• Castle Creek to acquire cell and gene therapy company Fibrocell (0)
• FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint (0)
• Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD (0)
• Aytu BioScience to acquire Innovus Pharmaceuticals (0)
• Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m (0)
• Xeris Pharmaceuticals bags GVOKE FDA approval for severe hypoglycemia (0)
• ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients (0)
• Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD (0)

The post Gemini Therapeutics appoints Jason Meyenburg as CEO appeared first on PharmaNewsDaily.com.